Intercept upgraded to Outperform from Market Perform at Leerink Leerink upgraded Intercept to Outperform citing an increased probability of success in NASH following last night's data. The firm raised its price target for shares to $445 from $270 saying it was encouraged by the removal of the prior imbalance in serious adverse events.
Intercept initiated with a Buy, $465 target at UBS UBS analyst Matthew Roden started shares of Intercept Pharmaceuticals with a Buy rating and $465 price target. Roden sees a favorable risk/reward ahead of the approval and commercial launch of the company's obeticholic acid, known as OCA, in primary biliary cirrhosis. Roden also thinks OCA's opportunity in nonalcoholic steatohepatitis is being undervalued at current share levels. Shares of Intercept closed yesterday up $2.53 to $274.44.